Novartis Buys Selexys As Competitors Stumble In Sickle Cell
Executive Summary
Novartis has exercised its option to acquire Selexys in a deal worth up to $665m, following data from the Phase II SUSTAIN trial of SelG1 in sickle cell disease. The move follows several recent failures in the space.
You may also be interested in...
Keeping Track: A Week Of Calm As Shutdown Drags On
The latest drug development news and highlights from our US FDA Performance Tracker.
GBT Picks Up Inclacumab From Roche's Bargain Bin
Five years after the Swiss major presented positive Phase II data on inclacumab as a treatment for patients with acute coronary syndromes, the drug has been snapped up by Global Blood Therapeutics for a tiny upfront fee to be developed for sickle cell disease.
Finance Watch: Former Alexion Execs Raise $37m To Launch Rare-Disease Focused RallyBio
Private Company Edition: Martin Mackay and two other former Alexion executives co-founded the rare disease start-up in January with a $37m Series A to kick things off. Also, Innovent raises $150m in venture cash, Tmunity adds $35m and Third Rock launches Cedilla.